Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity

NCT04940078 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04940078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04940078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
July 7, 2021
Completion date
February 16, 2022
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight